Kalaris Therapeutics
KLRS
79 hedge funds and large institutions have $640M invested in Kalaris Therapeutics in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 15 closing their positions.
66,400% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $2K
28% more capital invested
Capital invested by funds: $502M → $640M (+$138M)
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
0.06% less ownership
Funds ownership: 1.77% → 1.71% (-0.06%)
6% less funds holding
Funds holding: 84 → 79 (-5)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.8M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$9.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.91M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.4M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$25.7M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$15M |
| 3 |
State Street
Boston,
Massachusetts
|
-$9.98M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.82M |
| 5 |
Lido Advisors
Los Angeles,
California
|
-$6.85M |
KLRS Hedge Fund Activity: Q3 2021 in Review
79 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2021, worth a combined $640M — up 28% from $502M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of KLRS and 11 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 29 added.
The largest buyer was Fidelity Investments, adding an estimated $17.8M. The largest seller was AllianceBernstein, cutting an estimated $25.7M.
- 79 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2021, down from 84 in Q2 2021.
- Funds reported $640M of Kalaris Therapeutics stock for Q3 2021, up 28% quarter-over-quarter.
- 11 funds opened new Kalaris Therapeutics positions in Q3 2021 and 15 closed out, a net change of -4 holders.
- The largest Kalaris Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $17.8M added.
- The largest Kalaris Therapeutics seller in Q3 2021 was AllianceBernstein, an estimated $25.7M sold.
Based on aggregated 13F filings for Q3 2021.